Publications by authors named "Frederik Marme"

Claim this Profile
I
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
Milena Beierlein, Lothar Häberle, Naiba Nabieva, Nicolai Maass, Bahriye Aktas, Frederik Marme

Int J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
Fabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, Isabella Sala, Eleonora Pagan

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Philipp Harter, Frederik Marmé, Andrés Redondo, Alexander Reuss, Kristina Lindemann

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers.
Kai Doberstein, Johannes Panther, Eric Hahnen, Lisa Richters, Philip C Schouten

Commun Biol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[ 68 Ga]Ga-FAPI-46 PET/MRT Unveils Lymph Node Metastases and Changes Treatment Strategy in Recurrent Advanced High-grade Serous Ovarian Carcinoma Patient.
Marie Prochiner, Anna Hinterberger, Björn Wängler, Frederik Marmé, Freba Grawe

Clin Nucl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without Mutation.
Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, Jung Yun Lee, Lydia Gaba

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Germline and Somatic Mutations in Breast Cancer Treatment Strategies.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Kate Lawrenson, Siddhartha Kar, Karen McCue, Karoline Kuchenbaeker, Kyriaki Michailidou, Frederik Marme

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of early breast cancer: current status and perspectives.
Nikolas Tauber, Niklas Amann, Dominik Dannehl, Thomas M Deutsch, Moritz Dimpfl

Arch Gynecol Obstet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations.
Pauline Wimberger, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Markus Kerkmann

Eur J Surg Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study.
Andreas Schneeweiss, Peter A Fasching, Marc Thill, Marion van Mackelenbergh, Frederik Marme

J Cancer Res Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancer.
Philipp Harter, Frederik Marmé

Lancet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification.
Kristin Galas, Moritz Gleitsmann, Julia Rey, Christine Solbach, Isabell Witzel

NPJ Breast Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.
Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Frederik Marme

Geburtshilfe Frauenheilkd· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer.
Diana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Frederik Marme

Geburtshilfe Frauenheilkd· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
Fabio Conforti, Valentina Nekljudova, Isabella Sala, Roberto Ascari, Christine Solbach

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial.
Laura L Michel, Daniel Schwarz, Philipp Romar, Manuel Feisst, Daniel Hamberger

JAMA Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Study for Long-Term Cardiotoxicity in Dose-Dense Treated Cancer Patients.
Markus B Heckmann, Julia Lehmann, Daniel Finke, Florian Roll, Norbert Frey

Int J Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative).
Hope S Rugo, Peter Schmid, Sara M Tolaney, Frederik Marmé, Aditya Bardia

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer.
Hope S Rugo, Aditya Bardia, Peter Schmid, Sara M Tolaney, Anandaroop Dasgupta

Curr Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.
Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten Weber, Miguel Martin

Cancer Cell· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRIMA: captivated by the wizard of OS?
Frederik Marmé

J Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis